Introduction: Atopic dermatitis (AD) is a heterogeneous disease. Recent advancements in understanding AD pathogenesis resulted in the exponential expansion of its therapeutic pipeline, particularly following the success and FDA-approval of dupilumab. Different phenotypes of AD by age and ethnicity have also recently been described and clinical studies of emerging treatments will further clarify the role of each cytokine pathway in AD.Areas covered: We review the impressive repertoire of biologics for treatment of moderate-to-severe AD, including those targeting Th2, Th22, Th17/IL-23 and IgE. We highlight the scientific rationale behind each approach and provide a discussion of the most recent clinical efficacy and safety data.Expert opinion: AD is a complex disease and recent research has identified numerous endotypes, reinforcing the rationale for developing targeted therapeutics to antagonize these factors. Dupilumab has revolutionized AD treatment and its mechanistic studies also offer crucial insight into AD pathogenesis. Nevertheless, this biologic does not work for everyone, highlighting the need for a more precise approach to address the unique immune fingerprints of each AD subset. Ultimately targeted therapeutics will complement our understanding of the AD molecular map and help push AD management into an era of personalized medicine.

中文翻译：

---

生物制剂在特应性皮炎中的功效。

简介：特应性皮炎（AD）是一种异质性疾病。在了解AD发病机理方面的最新进展导致其治疗途径呈指数增长，特别是在dupilumab获得成功并获得FDA批准之后。最近还描述了按年龄和种族划分的不同的AD表型，新兴治疗方法的临床研究将进一步阐明每种细胞因子途径在AD中的作用。研究范围：我们综述了用于治疗中至重度AD的令人印象深刻的生物制剂库，包括针对Th2，Th22，Th17 / IL-23和IgE的那些。我们强调每种方法背后的科学原理，并提供有关最新临床疗效和安全性数据的讨论。专家意见：AD是一种复杂的疾病，最近的研究已经发现了许多内型，加强开发针对性疗法以对抗这些因素的理由。Dupilumab彻底改变了AD治疗，其机理研究也为AD发病机理提供了重要的见识。然而，这种生物制剂并非对所有人都有效，因此需要一种更精确的方法来解决每个AD子集的独特免疫指纹。最终靶向治疗将补充我们对AD分子图谱的理解，并帮助将AD管理推向个性化医学的时代。强调需要一种更精确的方法来处理每个AD子集的独特免疫指纹。最终靶向治疗将补充我们对AD分子图谱的理解，并帮助将AD管理推向个性化医学的时代。强调需要一种更精确的方法来处理每个AD子集的独特免疫指纹。最终靶向治疗将补充我们对AD分子图谱的理解，并帮助将AD管理推向个性化医学的时代。